10-Q · May 14, 2026
Atrium Therapeutics, Inc. reported Q1 2026 results highlighting a substantial increase in collaboration revenue to $19.6 million, thanks to a milestone payment, while gross and operating margins were impacted by rising…
Earnings analysis · 10-Q
RNA earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
Atrium reported Q2 2026 collaboration revenue of $3.004 million and diluted EPS of $(1.18), with revenue lower than the supplied Q1 history of $20 million and continued substantial operating losses. The company advanced…
Read full summary
Atrium reported Q2 2026 collaboration revenue of $3.004 million and diluted EPS of $(1.18), with revenue lower than the supplied Q1 history of $20 million and continued substantial operating losses. The company advanced ATR 1072 toward a 37-participant Phase 1/2 trial, obtained FDA IND clearance in July 2026 and earned a $15 million BMS milestone. Liquidity is supported by $72.3 million of cash and $191.6 million of short-term investments, but management expects those resources to fund operations for only at least 12 months from filing and acknowledges potential additional financing needs.
Reported figures
- Earnings per share
- $-1.18
- Segment
- Collaboration revenue: $3.004 million in Q2 2026; no additional operating segments were disclosed in the provided filing text.
What stood out
-
Q2 collaboration revenue totaled $3.004M
Q2 2026 collaboration revenue was $3.004 million, compared with $20 million of revenue in Q1 2026 in the supplied history, indicating a sequential decline in reported revenue.
-
$15M BMS milestone supports liquidity
The company received a $15 million BMS milestone payment in August 2026, providing a meaningful liquidity benefit for a clinical-stage company with no product revenue.
-
ATR 1072 reached Phase 1/2 readiness
ATR 1072 advanced into a planned 37-participant Phase 1/2 trial, and the FDA cleared the IND in July 2026; Health Canada also issued a No Objection Letter for planned Canadian sites.
-
Disclosure controls assessed effective
Management stated that disclosure controls and procedures were effective as of June 30, 2026, although processes and controls continue to evolve after becoming a standalone public company in February 2026.
What to watch
-
Continued losses and no product revenue
The company reported a net loss of $20.186 million for Q2 2026 and net losses of $36.8 million for the six months ended June 30, 2026; management expects significant losses for the foreseeable future.
-
Additional financing may be required
Cash, cash equivalents and short-term investments were $72.3 million and $191.6 million, respectively, as of June 30, 2026, but management only committed to liquidity for at least 12 months from filing and stated that additional financing may be needed sooner than planned.
-
Novartis-backed Avidity competition
The filing identifies direct competition from Avidity and Novartis in cardiac markets; Novartis now owns Avidity, while the Avidity License Agreement grants Avidity a non-exclusive, worldwide, irrevocable, royalty-free license for cardiovascular products outside the Lilly and BMS collaborations.
-
Early-stage clinical execution risk
ATR 1072's planned Phase 1/2 trial is designed for 37 participants, highlighting enrollment and execution risk in rare cardiac diseases with small patient populations; the company has never completed a clinical trial or submitted a BLA.
-
AI, privacy and cybersecurity exposure
The filing adds or expands risks related to AI use, including potential cybersecurity exposure, flawed research outputs and evolving regulation; GDPR penalties can reach the greater of €20 million or 4% of worldwide annual gross revenue.
Management's outlook
No numeric revenue or EPS guidance was provided. Management stated that existing cash, cash equivalents and short-term investments of $72.3 million and $191.6 million, respectively, are expected to fund operations for at least 12 months from the filing date.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.